At a glance
ClinicalIndex Comparison RecordPhase 2Active· 15 enrolled
Drug / intervention
CFI-400945 +1 moredrug
Likely dose
CFI-400945 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
In Brief
A Phase 2 clinical trial evaluating CFI-400945 and Durvalumab for Breast Cancer. Active but no longer recruiting, targeting 15 participants across 5 sites.
Detailed Summary
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesCanada
CollaboratorsAstraZeneca, University Health Network, Toronto
Timeline
Phase 2Active
20202021202220232024202520262027
First PostedNov 2019
Enrollment StartAug 2020
Primary CompletionSep 2022
TodayJul 2026
Study CompletionDec 2026
First PostedNov 25, 2019
Enrollment StartAug 10, 2020
Primary CompletionSep 15, 2022
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.6 years ago
Interventions
CFI-400945drug
CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
Durvalumabdrug
Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)